Publications
View AllBRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PURPOSE BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kin...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- ES
- Publications
- 2
- Citations
- 1,101
External Links
Identifiers
- ROR
- https://ror.org/01ynvwr63